Partial Rebreathing in the Treatment of Migraine With Aura
NCT ID: NCT03472417
Last Updated: 2018-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2016-11-30
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PArtial REbreathing for Migraine With Aura 1
NCT05546385
Cooling to Alleviate Migraine #3
NCT06874361
Pharmacologically Triggered Migraine Without Aura and Neuroimaging
NCT03143465
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
NCT03061734
New Methods for Evaluating Preventive Migraine Treatment
NCT07071506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active partial rebreathing device
Active partial rebreathing device
Dummy partial rebreathing device
Dummy partial rebreathing device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active partial rebreathing device
Dummy partial rebreathing device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Attack frequency of between one and six migraine-with-aura attacks per month over the last six months
* Adults (18-60 years)
* Age at onset of migraine \< 50 years
* If taking migraine prophylactic drugs, the dosis must have been stable for \> 3 months
* Must speak and understand Danish
Exclusion Criteria
* Chronic migraine, i.e. more than 15 headache days per month over the last three months
* Medication overuse headache
* More than six migraine-with-aura attacks per month
* Non-migraine headache on more than six days per month
* A typical duration between migraine-with-aura attacks of less than 48 hours
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital
OTHER
Rehaler
INDUSTRY
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Flemming W Bach, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pain and Headache Clinic, Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fuglsang CH, Johansen T, Kaila K, Kasch H, Bach FW. Treatment of acute migraine by a partial rebreathing device: A randomized controlled pilot study. Cephalalgia. 2018 Sep;38(10):1632-1643. doi: 10.1177/0333102418797285. Epub 2018 Aug 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-003683-39
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.